The Lancet Respiratory Medicine
-
1
[Editorial] The far-reaching effects of wildfire smoke
-
2
[Comment] Beyond efficacy: registries, equity, and outcomes in the ETI era
-
3
[Articles] Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry
-
4
[Comment] Rheumatoid arthritis-associated interstitial lung disease: between evidence, expertise, and guidelines
-
5
[Position Paper] Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement
-
6
[Articles] Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
-
7
[Comment] Sugammadex versus neostigmine and postoperative pulmonary complications: a word of caution
-
8
[Comment] Pulmonary fibrosis in chILD: bridging the gap
-
9
[Articles] Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study
-
10
[News] RSV vaccination and immunisation programmes accelerating worldwide
The Lancet Rheumatology
-
1
[Correspondence] The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice? – Authors' reply
-
2
[Viewpoint] Addressing the urgent need for clinical trials in chronic non-bacterial osteomyelitis
-
3
[Correspondence] The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
-
4
[Correspondence] The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
-
5
[News] Research in Brief
-
6
[Editorial] Translating progress into patient benefit in dermatomyositis
-
7
[Correspondence] The GO TEST Overture Trial: is the evidence sufficient to guide primary care practice?
-
8
[Correspondence] Low-dose and very low-dose glucocorticoids: which low is low risk? – Authors’ reply
-
9
[Correspondence] Low-dose and very low-dose glucocorticoids: which low is low risk?
-
10
[Articles] Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial
eClinicalMedicine
-
1
[Articles] Short, animated storytelling social contact videos reduce addiction stigma in the UK, USA, and South Africa: a randomised controlled trial of 13,397 participants
-
2
[Articles] A core outcome set for the wellbeing of healthcare professionals: an international Delphi consensus study
-
3
[Articles] Sex differences in tuberculosis incidence: a pooled analysis of 11 prospective cohort studies
-
4
[News] ESMO gynaecological cancers congress 2026
-
5
[Articles] Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up
-
6
[Articles] The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis
-
7
[Correspondence] Surprising conclusion due to a mathematic error?
-
8
[Articles] Physical activity and perinatal depression and anxiety: a global umbrella review and meta-meta-analysis
-
9
[Comment] Expression of concern—Donor characteristics and their impact on kidney transplantation outcomes: results from two nationwide instrumental variable analyses based on outcomes of donor kidney pairs accepted for transplantation
-
10
[Articles] Health-related quality of life after risk-reducing hysterectomy (PRESCORES): a cross-sectional study
The Lancet
-
1
[Articles] Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial
-
2
[World Report] Creating the building blocks of life
-
3
[Comment] Can physiotherapist-led care relieve the emergency physician bottleneck?
-
4
[Clinical Rounds] Generalised eruptive histiocytosis mimicking lymphoma relapse in a patient with previous diffuse large B-cell lymphoma
-
5
[Articles] Physiotherapist-led care for musculoskeletal conditions in the emergency department (RESHAP-ED): a randomised controlled trial with economic evaluation
-
6
[World Report] Russian medics reported to be complicit in torture
-
7
[Comment] Deep and durable lipoprotein(a) lowering: Kylo-11 advances RNA interference therapeutics
-
8
[Articles] Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
-
9
[Correspondence] Health should be key to transitioning away from fossil fuels
-
10
[Viewpoint] What makes a meta-analysis believable?
The Lancet Child & Adolescent Health
-
1
[Review] Methylation profile scores in child and adolescent health: a practical guide
-
2
[Health Policy] A global policy content analysis of congenital heart disease in national health priorities
-
3
[Editorial] Protect young people from the peptide boom
-
4
[Articles] Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6–9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
-
5
[Comment] Rotavirus vaccine success and the challenge of vaccine equity
-
6
[Articles] Rotavirus vaccine effectiveness against rotavirus and acute gastroenteritis mortality: an analysis of pooled case–control studies from the MNSSTER-V dataset
-
7
[Reflections] Chasing yesterday: a parent's reflection on developmental regression
-
8
[Comment] From waitlists to clinical action: pathway development and research priorities in childhood developmental regression
-
9
[Comment] From most vulnerable to most valuable: elevating children in the climate and health agenda
-
10
[Comment] Unleash the synergies: children's rights and the new strategy for child and adolescent health in Europe and Central Asia
The Lancet Diabetes & Endocrinology
-
1
[Review] From adiposity to multisystem morbidity: the case for weight loss as disease modification
-
2
[Correspondence] Time for personalised incretin titration
-
3
[Comment] The glucagon renaissance in obesity therapeutics
-
4
[Articles] Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
-
5
[Editorial] Diabetes in a warming world
-
6
[Comment] Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
-
7
[Articles] Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
-
8
[In Focus] Toxic chemicals: the fight for planetary health
-
9
[Comment] Type 2 diabetes management: weekly combination therapy comes of age?
-
10
[Articles] Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial
The Lancet Gastroenterology & Hepatology
-
1
[Articles] On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
-
2
[Articles] ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
-
3
[Review] The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence
-
4
[Comment] Propelling MASLD trials into the era of non-invasive tests
-
5
[Review] Bowel endometriosis: from pathogenesis to clinical management
-
6
[Review] Barrier restoration as a therapeutic strategy for disorders of gut–brain interaction
-
7
[Articles] Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial
-
8
[Review] Pathophysiology of irritable bowel syndrome
-
9
[Articles] The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial
-
10
[Comment] Launch of the Africa CDC toolkit for hepatitis B: bringing care closer to people in Africa
The Lancet Global Health
-
1
[Corrections] Correction to Lancet Glob Health 2026; 14: e702-13
-
2
[Correspondence] Beyond geography: conflict, displacement, and structural vulnerability in noma distribution in Nigeria
-
3
[Correspondence] Beyond geography: conflict, displacement, and structural vulnerability in noma distribution in Nigeria
-
4
[Correspondence] How to find panellists for a global health conference
-
5
[Correspondence] Structural silencing and the elephant in the room in global health
-
6
[Correspondence] Global health and its crises: laugh, but then what?
-
7
[Comment] Operational bottlenecks in the response to Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: a call to action
-
8
[Corrections] Correction to The burden of neurological conditions in north Africa and the Middle East, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet Glob Health 2024; 12: e960–82
-
9
[Corrections] Correction to Health in times of uncertainty in the eastern Mediterranean region, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Glob Health 2016; 4: e704-13
-
10
[Articles] Prevalence, characteristics, and clinical course of mpox-related ophthalmic disease (MBOTE-EYE): a prospective cohort study in South Kivu, Democratic Republic of the Congo
The Lancet Healthy Longevity
-
1
[Review] Community-acquired pneumonia in adults: acute and long-term complications
-
2
[Personal View] Reframing sarcopenia as a disease of the ageing motor system
-
3
[Editorial] Ending preventable heat-related deaths among older adults
-
4
[Personal View] Falls resilience framework: advancing from risk reduction to resilience building in older adults
-
5
[Comment] Adjunctive metformin for obesity and frailty in older people—puncturing inflated expectations?
-
6
[Articles] Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial
-
7
[Articles] Incidence of dementia after age 90 years and association with APOE genotype, race, and sex in the USA: the LifeAfter90 prospective cohort study
-
8
[Articles] Frailty, clinical outcomes, and treatment effects of a care bundle in acute intracerebral haemorrhage: a post-hoc analysis of the INTERACT3 trial
-
9
[Feature] Highlights of IAGG 2026
-
10
[Correspondence] Deprescribing trials need a rationale-first framework before choosing trial design